Key result
Acetylcholinesterase inhibitor use in dementia patients without a history of stroke was associated with a significantly decreased risk of ischemic stroke (HR 0.508).
Why the study?
Do acetylcholinesterase inhibitors reduce the risk of ischemic stroke in dementia patients over 50 years old without a history of stroke?
Cohort (n=10,364)
Do acetylcholinesterase inhibitors reduce the risk of ischemic stroke in dementia patients over 50 years old without a history of stroke?
In dementia patients without a history of stroke, the use of acetylcholinesterase inhibitors is associated with a significantly reduced risk of ischemic stroke, though it does not improve overall survival.
Should not yet change practice in dementia; leaves open a potential protective effect against ischemic stroke pending randomized data.
Patients with dementia are at increased risk of stroke. Acetylcholinesterase inhibitors (AChEIs) have endothelial function protection effects and anti-inflammatory properties. We investigated the ischemic stroke risk in AChEIs use in dementia patients without stroke history. Using Taiwan National Health Insurance Database from 1999 to 2008, 37,352 dementia patients over 50 years old without stroke history were eligible. The results were analyzed by propensity score-matched Cox proportional hazard models with competing risk adjustment. AChEIs users had lower incidence of ischemic stroke (160.3/10,000 person-years), compared to the propensity score-matched reference (240.8/10,000 person-years). The adjusted hazard ratio for ischemic stroke based on propensity score-matched Cox proportional hazard model was 0.508 (95% confidence interval, 0.434-0.594; P < 0.001). There was no significant difference in all-cause mortality between AChEIs users and nonusers. In conclusion, among dementia patients without previous ischemic stroke history, AChEIs treatment was associated with a decreased risk of ischemic stroke but not greater survival.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2016) conducted a cohort in Dementia (n=10,364). Acetylcholinesterase inhibitors vs. Nonusers was evaluated on Incidence of ischemic stroke (HR 0.508, 95% CI 0.434-0.594, p=<0.001). Acetylcholinesterase inhibitor use in dementia patients without a history of stroke was associated with a significantly decreased risk of ischemic stroke (HR 0.508).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: